Author(s): Klingemann H, Klingemann H, Klingemann H, Klingemann H
Abstract Share this page
Abstract T lymphocytes engineered to express a chimeric antigen receptor (CAR) are being celebrated as a major breakthrough of anticancer immunotherapy. Natural killer cells have not received similar attention as CAR effectors, although the use of these relatively short-lived cytotoxic cells is associated with several advantages.
This article was published in Oncoimmunology
and referenced in Immunotherapy: Open Access